Status: Not yet recruiting
Optimizing Ancillary Therapies With Immune Checkpoint Inhibitors for Solid Tumors (OAT ICI)
This study evaluates whether optimization of ancillary therapies can improve the efficacy of immune checkpoint therapy in participants with solid tumors. The ancillary therapies being optimized include the avoidance of daily acetaminophen and cannabis/THC/CBD while prescribing aspirin and loratadine. The goal is to see if optimizing these four drugs can improve the efficacy of the treatment compared to a matched historical control.
Participants needed: 98
Trial details
Phase: Phase 2Age: 18-99Biological sex: AllType: InterventionalSponsor: Val AdamsUpdated: Jun 22, 2026
Eligibility criteria
Solid tumor patients with measurable disease. Including patients with early stag... [+10]
Contraindication to immunotherapy, aspirin, or loratadine (including patients on... [+6]